Electromed, Inc. (NYSE:ELMD) Director Sells $1,016,920.59 in Stock

Electromed, Inc. (NYSE:ELMD) Director Andrew Summers sold 35,273 shares of the company’s stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $28.83, for a total value of $1,016,920.59. Following the completion of the transaction, the director now owns 129,190 shares of the company’s stock, valued at $3,724,547.70. This trade represents a 21.45 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Andrew Summers also recently made the following trade(s):

• On Monday, February 24th, Andrew Summers sold 50,751 shares of Electromed stock. The stock was sold at an average price of $27.30, for a total value of $1,385,502.30.
• On Wednesday, December 4th, Andrew Summers sold 12,731 shares of Electromed stock. The stock was sold at an average price of $29.98, for a total transaction of $381,675.38.
• On Monday, December 2nd, Andrew Summers sold 17,463 shares of Electromed stock. The shares were sold at an average price of $30.09, for a total transaction of $525,461.67.

Electromed Stock Performance

Shares of Electromed stock opened at $27.46 on Thursday. The stock has a market capitalization of $234.98 million, a P/E ratio of 36.61 and a beta of 0.33. Electromed, Inc. has a 52-week low of $13.74 and a 52-week high of $35.56. The stock’s 50-day simple moving average is $31.36 and its 200 day simple moving average is $25.59.

Wall Street Analyst Weigh In

ELMD has been the subject of several research analyst reports. B. Riley started coverage on shares of Electromed in a research note on Thursday, February 20th. They set a “buy” rating and a $38.00 price target for the company. StockNews.com downgraded Electromed from a “strong-buy” rating to a “buy” rating in a research report on Thursday.

Institutional Trading of Electromed

A number of institutional investors have recently modified their holdings of the business. Arrowstreet Capital Limited Partnership grew its stake in Electromed by 261.0% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 114,579 shares of the company’s stock valued at $3,386,000 after buying an additional 82,839 shares in the last quarter. Hunter Associates Investment Management LLC boosted its holdings in shares of Electromed by 12.3% in the third quarter. Hunter Associates Investment Management LLC now owns 102,450 shares of the company’s stock worth $2,199,000 after acquiring an additional 11,250 shares during the period. Northern Trust Corp grew its position in shares of Electromed by 14.1% in the fourth quarter. Northern Trust Corp now owns 65,350 shares of the company’s stock valued at $1,931,000 after purchasing an additional 8,086 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Electromed during the 4th quarter valued at $1,760,000. Finally, Susquehanna International Group LLP raised its stake in shares of Electromed by 121.8% during the 4th quarter. Susquehanna International Group LLP now owns 56,726 shares of the company’s stock valued at $1,676,000 after purchasing an additional 31,148 shares during the period. 40.82% of the stock is currently owned by hedge funds and other institutional investors.

Electromed Company Profile

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.